Atrial Fibrillation and Ventricular Tachyarrhythmias: Advancements for Better Outcomes

Author(s): Alireza Gheini, Afsoun Pourya, Ali Pooria*

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 20 , Issue 4 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Cardiac arrhythmias are associated with several cardiac diseases and are prevalent in people with or without structural and valvular abnormalities. Ventricular arrhythmias (VA) can be life threating and their onset require immediate medical attention. Similarly, atrial fibrillation and flutter lead to stroke, heart failure and even death. Optimal treatment of VA is variable and depends on the medical condition associated with the rhythm disorder (which includes reversible causes such as myocardial ischemia or pro-arrhythmic drugs). While an implanted cardioverter defibrillator is often indicated in secondary prevention of VA. This review highlights the newest advancements in these techniques and management of ventricular and atrial tachyarrhythmias, along with pharmacological therapy.

Keywords: Cardiac arrhythmias, heart failure, atrial tachyarrhythmias, ventricular arrhythmias (VA), valvular abnormalities, myocardial ischemia.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 4
Year: 2020
Published on: 13 January, 2021
Page: [249 - 259]
Pages: 11
DOI: 10.2174/1871529X20666201001143907
Price: $65

Article Metrics

PDF: 16